Mereo BioPharma Group PLC ADR (MREO) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.31 (+5.34%), Market cap $0.05B, 52-week low–high $0.24 ~ $2.94.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phas
Financial statements, price targets, institutional (13F) holdings and related news for Mereo BioPharma Group PLC ADR are updated in real time on BlackAll Trade.
Mereo BioPharma Group PLC ADR trades at $0.31 (+5.34%). Real-time quotes and charts are available on BlackAll Trade.
Mereo BioPharma Group PLC ADR has a market cap of about $0.05B.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Se